IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

MARCHETTI, GIULIA CARLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 17.848
NA - Nord America 17.415
AS - Asia 13.924
SA - Sud America 1.581
AF - Africa 382
OC - Oceania 70
Continente sconosciuto - Info sul continente non disponibili 21
Totale 51.241
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.712
GB - Regno Unito 6.113
CN - Cina 4.182
SG - Singapore 4.063
IT - Italia 3.604
DE - Germania 2.807
BR - Brasile 1.236
HK - Hong Kong 1.236
BD - Bangladesh 1.212
RU - Federazione Russa 1.106
VN - Vietnam 1.068
SE - Svezia 907
FR - Francia 723
IN - India 610
NL - Olanda 554
CA - Canada 518
FI - Finlandia 470
IE - Irlanda 398
ID - Indonesia 311
TR - Turchia 305
UA - Ucraina 288
KR - Corea 267
JP - Giappone 171
ES - Italia 155
PL - Polonia 112
DK - Danimarca 110
EU - Europa 104
MX - Messico 97
AR - Argentina 94
ZA - Sudafrica 92
CI - Costa d'Avorio 90
CO - Colombia 89
AT - Austria 85
BE - Belgio 78
IQ - Iraq 72
AU - Australia 66
GR - Grecia 58
CH - Svizzera 50
TW - Taiwan 48
PK - Pakistan 40
MA - Marocco 39
NO - Norvegia 39
PH - Filippine 38
EC - Ecuador 37
TH - Thailandia 35
VE - Venezuela 34
CL - Cile 32
UZ - Uzbekistan 32
MY - Malesia 31
AE - Emirati Arabi Uniti 25
ET - Etiopia 24
PT - Portogallo 24
RO - Romania 23
EG - Egitto 21
JM - Giamaica 21
PE - Perù 20
KE - Kenya 19
SA - Arabia Saudita 19
PY - Paraguay 18
TN - Tunisia 18
CZ - Repubblica Ceca 17
LT - Lituania 17
NG - Nigeria 16
KZ - Kazakistan 15
NP - Nepal 15
IL - Israele 14
IR - Iran 14
JO - Giordania 14
LB - Libano 14
LU - Lussemburgo 14
AZ - Azerbaigian 12
KG - Kirghizistan 11
HU - Ungheria 10
LV - Lettonia 10
MK - Macedonia 10
OM - Oman 10
TT - Trinidad e Tobago 10
BG - Bulgaria 9
BO - Bolivia 9
EE - Estonia 9
PA - Panama 9
AL - Albania 8
CR - Costa Rica 8
DZ - Algeria 8
HN - Honduras 8
UY - Uruguay 8
ZW - Zimbabwe 8
RS - Serbia 7
SN - Senegal 7
UG - Uganda 7
HR - Croazia 6
NI - Nicaragua 6
PS - Palestinian Territory 6
ZM - Zambia 6
BY - Bielorussia 5
DO - Repubblica Dominicana 5
GT - Guatemala 5
LY - Libia 5
MT - Malta 5
QA - Qatar 5
Totale 51.232
Salva come PNG Salva come JPEG
Città #
Southend 5.591
Singapore 2.252
Ashburn 1.839
Dallas 1.790
Frankfurt am Main 1.143
Milan 1.124
Hong Kong 1.107
San Jose 922
Chandler 864
Fairfield 785
Beijing 783
Seattle 601
Los Angeles 533
Council Bluffs 526
Hanover 484
Wilmington 442
Ann Arbor 438
Hefei 407
Dublin 395
New York 394
Princeton 367
Woodbridge 357
Santa Clara 354
Houston 351
Ho Chi Minh City 322
Boardman 312
Hanoi 288
Rome 274
Chicago 273
Toronto 255
Helsinki 254
Bengaluru 253
Jakarta 242
Cambridge 241
Buffalo 231
Dearborn 231
Lauterbourg 226
Jacksonville 213
Moscow 213
Guangzhou 192
The Dalles 174
Nanjing 171
Shanghai 139
Phoenix 134
São Paulo 132
Des Moines 131
Munich 128
Redmond 124
Tokyo 122
Mountain View 111
Columbus 101
Grafing 98
Naples 96
Cangzhou 95
Seoul 95
Istanbul 91
Nuremberg 90
Abidjan 89
Salt Lake City 88
Warsaw 87
Redwood City 82
Hangzhou 79
Serra 77
Sakarya 69
Bogotá 68
Andover 66
Turin 66
Atlanta 65
Brussels 61
Jinan 61
Shenyang 61
Washington 61
Lappeenranta 60
Mumbai 59
Haiphong 57
Shenzhen 57
Tianjin 57
Changsha 56
London 54
San Diego 53
Montreal 52
Orem 52
Da Nang 51
Amsterdam 50
Wuhan 50
Bologna 48
Ottawa 48
Silver Spring 48
Berlin 47
Montréal 47
Groningen 46
Kiez 45
Vienna 45
Somerville 44
Madrid 43
Paris 43
Turku 42
Zhengzhou 42
Rio de Janeiro 41
Tampa 41
Totale 32.359
Salva come PNG Salva come JPEG
Nome #
Association between peripheral T-Lymphocyte activation and impaired bone mineral density in HIV-infected patients 816
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 582
Quality control by Flow Cytometry and Media Fill Test of autologous leukocytes marked with 99mTc-HMPAO to be used for the “In Vivo” infection diagnosis: A pilot study 472
Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study). 471
Inflammation and Intracellular Exposure of Dolutegravir, Darunavir, Tenofovir and Emtricitabine in People living with HIV 470
Immunomodulation induced by tucaresol in HIV infection: results of a 16 week pilot Phase I/II trial 393
HPV infection in a cohort of HIV-positive men and women : prevalence of oncogenic genotypes and predictors of mucosal damage at genital and oral sites 382
Rhodococcus equi infection in a patient with spinocellular carcinoma of unknown origin 377
CD4+ T cell depletion, immune activation and increased production of regulatory T cells in the thymus of HIV-infected individuals 374
Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial 374
Spoligotyping and mycobacterium tuberculosis 373
Clinical characteristics and outcomes of vaccinated patients hospitalised with SARS-CoV-2 breakthrough infection: Multi-IPV, a multicentre study in Northern Italy 366
T-Cell Phenotypes, Apoptosis and Inflammation in HIV+ Patients on Virologically Effective cART with Early Atherosclerosis 363
Fully immunocompetent CD8+ T lymphocytes are present in autologous haematopoietic stem cell transplantation recipients despite an ineffectual T-helper response 354
Early initiation of highly active antiretroviral therapy fails to reverse immunovirological abnormalities in gut-associated lymphoid tissue induced by acute HIV infection 353
Evaluation of PCR in detection of Mycobacterium tuberculosis from formalin-fixed, paraffin-embedded tissues : comparison of four amplifiaction assays 347
Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis 345
Qualitative immune modulation by Interleukin-2 (IL-2) adjuvant therapy in immunological non responder HIV-infected patients 327
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 324
Mucosal cell populations may contribute to peripheral immune abnormalities in HIV-infected subjects introducing cART with moderate immune-suppression 324
Factors associated with HPV-DNA clearance in a cohort of HIV-positive patients : role of cART and gender 323
A PCR-colorimetric microwell plate hybridization assay for detection of Mycobacterium tuberculosis and M. avium from culture samples and Ziehl-Neelsen-positive smears 322
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 321
Reduced central memory CD4+ T cells and increased T-Cell activation characterise treatment-naive patients newly diagnosed at late stage of HIV infection 320
Increased bone marrow interleukin-7 (IL-7)/IL-7R levels but reduced IL-7 responsiveness in HIV-Positive patients lacking CD4+ gain on antiviral therapy 316
Evaluation of the effect of protective genetic variants on cART success in HIV-1-infected patients 316
PCR-hybridization assay for Mycobacterium avium complex: optimization of detection in peripheral blood from humans 312
HIV-DNA decrease during treatment in primary HIV-1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTION) clinical trial 310
Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients 306
Is weak CD4+ gain in the course of suppressive combination antiretroviral therapy for HIV infection a current clinical challenge? A case report and brief review of the literature 303
Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial 301
Maraviroc intensification for HIV-1-positive immunological non-responders (INRs) despite virological suppression during HAART 297
Evidence for polymicrobic flora translocating in peripheral blood of HIV-infected patients with poor immune response to antiretroviral therapy 296
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts : Data from the Icona Foundation Cohort 296
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 296
Six-month immune responses to mRNA-1273 vaccine in combination antiretroviral therapy treated late presenter people with HIV according to previous SARS-CoV-2 infection 295
HIV-infected long-term nonprogressors display a unique correlative pattern between the interleukin-7/interleukin-7 receptor circuit and T-cell homeostasis 292
A 20-year-old girl with an unusual febrile illness 292
Noncirrhotic portal hypertension in HIV-infected patients: a case control evaluation and review of the literature 291
Invariant Natural Killer T (iNKT) cells in HAART-treated, HIV-positive patients with bone and cardiovascular impairment 289
Assessment of radiological vertebral fractures in HIV-infected patients : clinical implications and predictive factors 289
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 288
An outbreak of multidrug-resistant tuberculosis involving HIV-infected patients of two hospitals in Milan, Italy 287
Detrimental effect of atazanavir plasma concentrations on total serum bilirubin levels in the presence of UGT1A1 polymorphisms 287
The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy : clinical risk, immunological gaps, and therapeutic options 284
Virological response and retention in care according to time of starting ART in Italy: Data from the Icona Foundation Study cohort 284
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort 282
Primary HIV infection features colonic damage and neutrophil inflammation yet containment of microbial translocation 279
Microbial translocation in the pathogenesis of HIV infection and AIDS 279
Cognitive Neuro-Rehabilitation of HIV-Associated Neurocognitive Disorders : Case Reports of A New Computer-Based Restorative Approach In 3 Hiv-Positive Cart-Treated Patients 278
T-cell phenotype and function following a first cART regimen containing either a protease inhibitor or a non-nucleoside retrotranscriptase inhibitor in HIV-infected late presenters: results from a retrospective, ex vivo study 277
Association between abdominal aortic calcifications, bone mineral density and vertebral fractures in a cohort of HIV-positive patients 276
Long-Term Suppressive cART Is Not Sufficient to Restore Intestinal Permeability and Gut Microbiota Compositional Changes 264
Therapeutic Effect of Iron Citrate in Blocking Calcium Deposition in High Pi-Calcified VSMC: Role of Autophagy and Apoptosis 263
Comparison between Spoligotyping and IS6110 Restriction Fragment Polymorphism in Molecular Genotyping Analysis of Mycobacterium tuberculosis strains 263
Enhancing care for people living with HIV: current and future monitoring approaches 262
Impact of daily versus weekly service of infectious diseases consultation on hospital antimicrobial consumption : a retrospective study. 261
Abacavir and cardiovascular risk in HIV-infected patients: does T-lymphocyte hyperactivation exert a pathogenic role? 260
Viro-immunological characterization of naïve patients with high cerebrospinal fluid (CSF) HIV RNA 259
Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study 258
Growth Differentiation Factor 15 (GDF-15) Levels Associate with Lower Survival in Chronic Kidney Disease Patients with COVID-19 257
Impairment of platelet function in both mild and severe COVID-19 patients 256
Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy 255
Unconventional T cells in chronic hepatitis B patients on long-term suppressive therapy with tenofovir followed by a Peg-IFN add-on strategy: A randomized study 254
Nested polymerase chain reaction for mycobacterium tuberculosis IS6110 sequence on formalin-fixed paraffin-embedded tissues with granulomatous diseases for rapid diagnosis of tuberculosis 248
Serum alpha-Fetoprotein levels predict early virologic response in HIV-positive subjects treated for chronic hepatitis C 247
Efficacy of Maraviroc (MVC) as intensification strategy in immunological non-responder (INR) HIV-1-infected patients treated with HAART 247
Role of in vitro stimulation with lipopolysaccharide on T-Cell activation in HIV-infected antiretroviral-treated patients 247
Sensitivity of SARS-CoV-2 Detection With Nasopharyngeal Swabs 247
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort 247
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus 245
Skewed T-cell maturation and function in HIV-infected patients failing CD4+ recovery upon long-term virologically suppressive HAART 244
Determinants of worse liver‐related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort 243
Association between CSF and peripheral markers of immune-activation/inflammation and elevated intrathecal HIV-RNA levels in a cohort of HIV-infected antiretroviral naıve individuals 243
Biomarkers of aging in HIV: inflammation and the microbiome 241
Untangling the immunological implications of nadir on CD4+ cell recovery during suppressive highly active antiretroviral therapy 240
Non-AIDS defining cancers in the D:A:D Study-time trends and predictors of survival : a cohort study 238
Monitoring of transmission of tuberculosis between wild boars and cattle : genotypical analysis of strains by molecular epidemiology techniques 236
Interleukin-2 immunotherapy exerts a differential effect on CD4 and CD8 T cell dynamics 234
Cell-Mediated Immunity in HIV-Infected Males With Human Papillomavirus-Related Anal Dysplastic Lesions 234
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 233
Molecular epidemiology study of exogenous reinfection in an area with a low incidence of tuberculosis 232
Gut barrier structure, mucosal immunity and intestinal microbiota in the pathogenesis and treatment of HIV infection 232
Declining mortality rate of hospitalised patients in the second wave of the COVID-19 epidemics in Italy : Risk factors and the age-specific patterns 232
IL-7/IL-7 receptor system regulation following IL-2 immunotherapy in HIV-infected patients 231
Dyslipidaemia after switch to tenofovir alafenamide (TAF)-based cART regimens in a cohort of HIV-positive patients: what clinical relevance? 231
CD4 cell count and the risk of infective and non-infective serious non-AIDS events in HIV-positive persons seen for care in Italy 230
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy : an observational cohort study 229
Discontinuation of initial antiretroviral therapy in clinical practice : Moving toward individualized therapy 228
CD8+ hyperactivation and senescence correlate with early carotid intima-media thickness in HIV+ patients with no cardiovascular disease 227
Sudden cardiac death in a young HIV-positive man on effective antiretroviral therapy 227
Clinical and viro-immunological correlates of HIV associated neurocognitive disorders (HAND) in a cohort of antiretroviral-naïve HIV-infected patients 226
Nosocomial bacterial pneumonia in HIV-infected patients : risk factors for adverse outcome and implications for rational empiric antibiotic therapy 225
A case of Costochondral abscess due to Corynebacterium minutissimum in an HIV-infected patient 224
Clinical Outcome and 7-Day Virological Clearance in High-Risk Patients with Mild–Moderate COVID-19 Treated with Molnupiravir, Nirmatrelvir/Ritonavir, or Remdesivir 222
Osteopenia/osteoporosis in HIV infected patients are associated with reduced expression and production of IL-7RA in CD8+T cells 221
Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients : results from the Icona Foundation study 219
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals : an observational cohort study 218
The challenge of IL-2 Immunotherapy in HIV Disease : “No through Road” or turning point? 217
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 217
Totale 29.185
Salva come PNG Salva come JPEG
Categoria #
all - tutte 138.724
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 138.724
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021116 0 0 0 0 0 0 0 0 0 0 0 116
2021/20223.714 298 271 240 178 223 171 323 625 417 329 163 476
2022/20233.280 385 330 262 364 350 596 87 166 430 45 184 81
2023/20243.172 129 151 112 181 560 257 287 251 136 248 388 472
2024/20258.168 362 615 244 741 507 419 419 626 441 991 948 1.855
2025/202619.703 1.636 2.270 2.066 1.502 1.510 1.146 2.270 881 1.779 1.307 2.581 755
Totale 53.142